Despite many brilliant scientific discoveries, getting a new drug approved remains a very expensive and time-consuming process. Currently, biotech companies are facing increasing challenges when it comes to reducing R&D costs and bringing therapies to patients much faster. To meet these needs, there is a requirement for a complete change in the R&D approach. Faster Drug Discovery Pipelines are becoming essential by combining artificial intelligence, automation, robotics, and advanced laboratory technologies to accelerate research, improve accuracy, and shorten the journey from initial discovery to successful drug development.
The key to solving these problems does not lie in making a single amazing scientific breakthrough. Instead, it consists of an ecosystem of interrelated technologies that help companies rethink target identification, validation, and scaling of new drugs.
Why Traditional Drug Discovery Processes Are No Longer Efficient
The figures regarding the classical drug development process speak volumes. According to the Congressional Budget Office, it usually takes more than ten years to get a new drug approved after the initial discovery process. Furthermore, the financial burden is extremely high.
As per a study conducted by Deloitte, the average cost of developing a new asset has been growing significantly in recent years, while clinical trial attrition rates have remained high. Furthermore, this situation is aggravated by the increasing complexity of precision medicine, biologics, and genomics. Classic approaches based mainly on manual work in the laboratory reach their boundaries.
Manual sample preparation and analogue data tracking lead to significant bottlenecks in the R&D process. In current conditions, using these methods in the laboratory is not only inefficient but also a serious business risk, as modern investors are no longer prepared to finance such outdated solutions.
How AI Changes Target Identification and Drug Design Process
Artificial intelligence has moved from theory to practice and has become a tool for target identification. With the help of machine learning algorithms, research teams are able to analyse large biological datasets and make predictions regarding protein structures and molecular interactions within seconds instead of months.
As per representatives of the European Molecular Biology Laboratory, this technology enables researchers to choose the most promising drug candidates without even touching the pipettes. It helps significantly reduce the timeline of the discovery process.
However, it should be understood that any computational models require verification. That is why the true power of AI lies in the combination with the physical laboratory. To validate all predictions of the silicon-based models, there is a need to have a bridge to test all these models in the laboratory.
How Robotics and Automation Improve the Workflow
To be able to work in sync with the predictions made by the computational models, laboratories use advanced robots for sample preparation and high-throughput screening. These methods have completely revolutionised the modern laboratory environment.
Thanks to the reduction of manual work, these systems help scale up the throughput of experiments exponentially without the necessity to hire more staff. At the same time, the standardised protocols used in the automation help achieve the same results for the same assays that have been performed by different research teams located in different cities around the globe.
What Benefits Bring Automation to Life Science Research
Besides the obvious operational benefits, automation brings several others. One of the biggest challenges in life science research is reproducibility, which has become the key focus of policy updates by the National Institutes of Health.
Manual sample preparations involve minor fluctuations that make the data obtained not completely reliable. But the automation process allows for the removal of all this human variability and the receipt of pristine and consistent datasets. If all experiments are standardised, there will be fewer errors, and research programmes will scale easily, facilitating the transition to the next phase: clinical trials.
Why Precision in Liquid Handling Is Critical for Modern Drug Discovery
Despite the fact that automation and AI technologies have become popular among scientists and attract media attention, the successful operation of these systems depends on the precision of the basic processes. If the basic mechanics of the experiment fail, the whole automated process collapses.
Accurate sample transfer is crucial for reproducible research. That is why many laboratories invest in purchasing an automated liquid handler that ensures the precise dispensing of fluids, eliminates human variability, and supports high throughput.
High Throughput Experiments Require High Precision
In the context of high-throughput experiments, the slightest deviation in the volume of the liquid used may affect the results dramatically. Because of that, the precision in fluid dynamics should be ensured in order to protect investments made in the upstream AI and downstream analytics.
This is a purely operational aspect of the drug discovery process; your discovery process is only as efficient as the most precise fluid transfer. The precision at this stage will guarantee that high data pools will not be compromised because of mechanical deviations.
The Ultimate Advantage Will Belong to the Connected Laboratory Ecosystems
In the future, success will not belong to the companies that have the fastest separate tools, but to those that are able to create a fully connected laboratory ecosystem. The future belongs to the connected laboratory ecosystem. The connection of the AI discovery platforms, physical instruments, and cloud-based systems will create a closed loop for the research process.
The connection of the instruments to the cloud provides the ability to perform real-time analytics and remote monitoring, which paves the way for the full automation of laboratories. Such executives will have a great long-term advantage compared to competitors with fragmented and isolated operations.
Conclusion
The modern drug discovery process has moved from being labour-intensive and reliant on trial-and-error to becoming a technologically advanced sphere. It does not require more time invested manually. Organisations that are smart enough to integrate AI, robotics, and automation will dramatically increase research productivity and reduce the time to market.
